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Background: Microwave ablation (MWA) is used to treat patients with unresectable liver cancer. Our institution
applied a novel microwave generator capable of automatically adjusting energy levels based on feedback related to
tissue permittivity. This approach is meant to facilitate ablations over larger areas and provide results of greater
predictablility. This paper reports on the safety, efficacy, and feasibility of this new system in the treatment of
patients with large liver tumors.
Methods: Between July 2012 and December 2012, a total of 23 patients with malignant liver tumors exceeding
4 cm in diameter underwent surgical MWA using a 902–928 MHz generator. The proposed system used a 14-gauge
antenna without internal-cooling. Follow up on tumor recurrence was performed using contrast-enhanced
computed tomography or magnetic resonance imaging at 1 month and then at 3 month intervals for a period
of at least 12 months following ablation.
Results: Among the cancers treated, 10 were primary hepatocellular carcinomas (HCCs) and 13 were metastatic
lesions from primary colorectal cancer (CRLM). The mean tumor size was 5.40 cm (range of 4.0-7.0 cm). A total of 18
patients underwent MWA via open surgery, and 5 received laparoscopic MWA. The mean ablation time was
1982 seconds, with a range of 900-3600 seconds, and the median number of ablation sessions was 2.0 (range of
1–4 sessions). The rate of complete ablation, as defined by a total loss of contrast-enhancement one month
post-treatment, was 82.6% (19 of 23 patients), and the rate of local recurrence was 26.3% (5 of 19 patients). For
tumors with a diameter of 4.0-7.0 cm, the technical success rate of MWA was higher for HCC patients (70%) than
for metastatic liver cancer (53.8%) patients; however, the difference was not statistically significant. All patients
survived throughout the observation period, and the morbidity rate was 8.6%.
Conclusions: MWA treatment using the proposed system with tissue permittivity feedback control resulted in a
high rate of complete ablation and reduced morbidity. This approach proved to be a fast, easy, and effective option
for the ablation of large liver cancers, particularly HCCs.
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Surgical intervention is the gold standard of treatment
for liver cancers; however, many patients are unable to
undergo liver resection due to a diminished hepatic
reservoir, the multifocal nature of tumors, or severe co-
morbidities. These challenges led to the development of
local tumor ablation as a treatment for small liver tumors
which are not amenable to surgical resection [1].
Radiofrequency ablation (RFA) is the most popular
local ablative modality due to its efficacy and safety
[2,3]. Nonetheless, the high rate of therapeutic failure,
particularly for larger tumors, is an issue of concern
[3,4]. Another problem is the difficulty in achieving
complete tumor ablation near large vessels due to the
heat-sink effect, which decreases the efficacy of heating
and diminishes the size of the ablation zone [5].
Microwave ablation (MWA) therapy has been widely
applied in the treatment of liver and lung tumors [6]. In
this procedure, microwave radiation creates a hyperther-
mic zone by agitating dipole water molecule in tissue,
thereby increasing kinetic energy in the area. Recent
advances in engineering have facilitated the development
of advanced MW devices that are capable of performing
larger ablations in a shorter period of time, compared
with traditional RF systems [7,8].
Furthermore, the size and shape of the MWA zone is
believed to be more consistent and less vulnerable to the
heat-sink effect that arises from large vessels adjacent to
the lesion [9]. In this way, MWA can overcome a number
of limitations of RFA to improve the efficacy of treat-
ment, particularly in the treatment of large tumors.
The newly designed Medwaves AveCure MWA system
(San Diego, CA, USA) features a tissue permittivity feed-
back control mechanism that provides real-time monitor-
ing of ablation conditions as well as the ability to modulate
the power and frequency of MW energy [10]. The heating
of biologically active tissue can alter the properties of
permittivity, such that energy deposition can be maximized
and reverse power (a measure of reflectivity), can be mini-
mized. An increase in the amount of forward power leads
to an increase in active heating, which is capable of
inducing a large ablation zone and eradicating larger
tumors [10].
The aim of this study was to evaluate the safety and
efficacy of this novel MW system in the treatment of
liver cancers exceeding 4 cm.
Methods
Patient population
A total of 23 patients with evidence of primary or meta-
static liver cancer (ranging 4-7 cm in diameter) under-
went MWA between July 2012 and December 2012 at
the National Taiwan University Hospital. Diagnoses were
established by triphasic computed tomography (CT) orpathologic analysis of specimens. No evidence of vascular
invasion or extra-hepatic metastases was observed in
these patients during tumor ablation. Complete tumor
resection was not feasible in 21 patients, and the resect-
ability of liver cancers was defined simply as tumors that
can be resected completely, leaving an adequate liver
remnant. The criteria for adequate reservoir means at
least 20% of the total estimated liver volume for normal
parenchyma, 40% if the liver is injured by chemotherapy
or steatosis, or 40%–70% in the presence of liver fibrosis
or cirrhosis, depending on the degree of underlying
hepatic dysfunction estimated by pre-operative indocya-
nine green clearance test. There were two patient with
large metastatic colon cancers refused to receive liver
resection even their liver reservoirs are adequate for liver
resection. They both used to suffer from complicated
colon operation and hesitate to receive abdominal oper-
ation again, so they underwent local ablation. All of the
enrolled patients provided informed consent before
undergoing the procedure and this study was approved
by National Taiwan University Hospital Research Ethics
Committee.
MWA system
This study evaluated the ability of the Medwaves
Microwave Generator with a 14 G antenna (straight
needle, shaft length of 15 cm with a 4 cm active micro-
wave field radiating proximally from the tip) to deliver
MW energy into the target area. The system includes
temperature sensors integrated within the probes as
well as intelligent permittivity feedback control. This
feedback control enables real-time monitoring of abla-
tion conditions as well as the ability to modulate power
(10–32 Watts) or frequency (902 MHz – 928 MHz)
according to changes in the ablation zone. The feedback
control system further maintains the permittivity of tissue
and enables tissue to adapt to microwave radiation. This in
turn makes it possible to maximize energy deposition and
minimize reverse power. Ablation cycles of 600 seconds
resulted in ovoid ablation zones exceeding 4.5 cm in diam-
eter. Microwave tumor ablation by this equipment is a
standard clinical practice in Taiwan, not sole for the pur-
poses of the study.
Ablation technique
Patients were selected to undergo surgical MWA either by
open surgery or using laparoscopy. The type of procedure
was selected according to tumor location, comorbidities,
and patient preference. MWA was performed with ultra-
sound guidance under general anesthesia. A 14-gauge
antenna was inserted and positioned at a designated loca-
tion within the tumors, and the generator was powered in
accordance with the manufacturer’s recommendations for
sessions of 600 or 900 seconds. In administering MWA,
Table 1 Patients characteristics
Variable Value Range
Age(y), mean ± SD 65.82 ± 12.05 36-82
Gender (male/female), n 15/8
Albumin (g/dL), mean ± SD 3.93 ± 0.61 2.5-5.2
Platelet count (x 103/μL), mean ± SD 218.3 ± 108.5 75-592
International normalized ratio 1.01 ± 0.07 0.93-1.16
Aspartate aminotransferase (IU/L), mean ± SD 62.13 ± 50.12 19-196
Alanine aminotransferase (IU/L), mean ± SD 53.52. ± 62.02 10-267
Total bilirubin (mg/dL), mean ± SD 0.61 ± 0.25 0.30-1.13
Etiology, n (%)
Hepatocellular carcinoma 10 (43.5)
Metastatic colorectal cancer 13 (56.5)




Table 2 Characteristics of tumor and MWA procedures
Variable Value Range
Tumor size (cm), mean ± SD 5.41 ± 0.86 4-7
MWA procedure, n (%)
Open approach 18 (78.3)
Laparosopic approach 5 (21.7)
Ablation session, (n), mean ± SD 2.48 ± 0.79 1-4
Ablation time (sec), mean ± SD 1983 ± 687.3 900-3600
Liang et al. BMC Surgery 2014, 14:82 Page 3 of 7
http://www.biomedcentral.com/1471-2482/14/82we sought the complete destruction of tumors. This ne-
cessitated detailed pre-operative planning regarding the
placement of antennae, energy delivery settings, and
ablation time. Generally, the tip of the antenna is posi-
tioned at the bottom of the tumor margin for the first
application. The antenna is then withdrawn in increments
of 1-2 cm as multiple, overlapping ablations are per-
formed. Changing the direction of the tip or re-inserting
the antenna can also be considered to ensure that the
ablation zone covers the entire area of the tumor with a
safe margin exceeding 0.5 cm.
During ablation, observation of an expanding hypere-
chogenic area under sonography was used to judge the
shape of the ablation zone. These changes are visible dur-
ing ablation; however, they tend to diminish more rapidly
in MWA than in RFA. Following ablation, the antenna
was removed directly without performing a tract ablation
procedure.
Evaluation of therapeutic efficacy
All patients underwent follow-up with contrast-enhanced
CT at 1 month post-ablation, and then once every
3 months using cross-sectional contrasted imaging and
serum assays of tumor markers. Complete ablation was
defined as a uniform loss of contrast enhancement in the
area previously occupied by the tumor. Local recurrence
was defined as tumor recurrence in the treated area
following ablation therapy observed by contrast-enhanced
image as enhanced lesions. The technical success of MWA
was assessed according to the criteria; complete ablation
with no local recurrence during a one-year follow-up. All
statistical analyses were performed using SPSS17.0 software.
Comparisons were performed using the Fisher exact test
for categorical data and paired t-test for quantitative data.
A p-value of less than 0.05 was assumed to be statistically
significant.
Results
This study included 15 males and 8 females. Participants
had a mean age of 65.8 years (range of 36–82 years), and
the follow-up period for every patient was at least
12 months (mean of 16.5 months). Among the 23 liver
tumors from the 23 patients, 10 were primary hepato-
cellular carcinomas (HCCs) and 13 tumors were
metastatic lesions from primary colorectal cancer
(CRLM). No extra-hepatic malignancy was noted prior
to the administration of MWA. Liver function status
was classified as Child-Pugh class A in 15 patients
(65.2%), Child-Pugh class B in 7 patients (30.5%), and
Child-Pugh class C in 1 patient (4.3%). Individual patient
demographics are listed in Table 1.
The locations of tumors were evenly distributed on
the right and left lobes, with one tumor located within
the caudate. The tumors had a mean diameter of5.41 ± 0.86 cm (range of 4–7 cm). Characteristics of the
tumors are listed in Table 2. Among the 23 patients, 5
underwent laparoscopic MWA and 18 underwent open
surgical MWA. All procedures were completed without
incident. The mean ablation time, defined as the total
time the generator was active for ablation, was 1982 ±
687.3 seconds (range of 900-3600 s). The average abla-
tion session was 2.48 ± 0.79 (range of 1-4).
Demographic profiles of HCC and CRLM patients are
listed in Table 3. The rate of complete ablation was
82.6% (90% and 76.9% for HCC and CRLM patients,
respectively). The local recurrence rate was 26.3% (90%
and 84.6% for HCC and CRLM patients, respectively).
Technical success was achieved in 14 of the 23 tumors
(60.9% overall, or 70% for HCC and 53.8% for CRLM).
The rates of complete ablation, local recurrence, and
technical success were better for HCC than for CRLM;
however, the difference in local recurrence rates was not
significant (Table 4). Two of the patients with CRLM
and one patient with HCC developed distant recurrence
within the follow-up period.
No immediate complications were recorded during any
of the ablation procedures. Two patients did experience
Table 3 Comparison of Variables According to cancer
type
Variable HCC (N = 10) Metastatic liver
cancer (N = 13)
Age(y), mean ± SD 61.5 ± 12.5 69.2 ± 9.08
Male sex, n (%) 8 (80.0) 7 (53.8)
Child-Pugh score, n (%)
A 5 (50) 9 (69.2)
B 4 (50) 4 (30.8)
C 1 (10) 0 (0)
Tumor location, n (%)
Left lobe 4 (40) 3 (23.1)
Right lobe 5 (50) 10 (76.9)
Caudal lobe 1 (10) 0 (0)
Major vessel attachment, n (%) 6 (60) 7 (53.8)
Tumor size (cm), mean ± SD 5.70 ± 1.49 5.31 ± 0.89
MWA procedure, n (%)
Open approach 8 (80) 10 (76.9)
Laparosopic approach 2 (20) 3 (23.1)
Ablation session, n, mean ± SD 2.80 ± 0.79 2.23 ± 0.73
Ablation time (sec), mean ± SD 2190 ± 721.8 1823 ± 641.8
Liang et al. BMC Surgery 2014, 14:82 Page 4 of 7
http://www.biomedcentral.com/1471-2482/14/82mild dilated intrahepatic bile ducts without jaundice-like
symptoms; however, no other clinically relevant compli-
cations were observed. Additionally, no cases of mortality
were noted during the follow-up period. The mean dur-
ation of hospital stay for patients who underwent laparo-
scopic MWA and open surgical MWA was 6.0 ±
0.82 days and 3.6 ± 0.49 days, respectively. This indicates
that the laparoscopic approach resulted in shorterTable 4 Comparison of outcome according to cancer type
Variable HCC (N = 10) Metastatic liver
cancer (N = 13)
Technique success (%) 7 (70.0) 7 (53.8)
Laparoscopic approach (%) 2 (100) 2 (66.7)
Open approach (%) 5 (62.5) 5 (50.0)
Complete ablation 9 (90.0) 10 (76.9)
Laparoscopic approach (%) 2 (100) 3 (100)
Open approach (%) 7 (87.5) 7 (70.0)
Local recurrence 2 (22.3) 3 (30.0)
Laparoscopic approach (%) 0 (0) 1 (33.3)
Open approach (%) 2 (28.6) 2 (28.6)
Hospital stay (d), mean ± SD 5.70 ± 1.49 5.2 ± 1.11
Laparoscopic approach 3.5 ± 0.71 3.67 ± 0.58
Open approach 6.25 ± 1.03 5.86 ± 0.63
Complication, n (%)
Bile duct dilatation, n (%) 1 (10.0) 1 (7.69)hospital stays, compared to open surgery. No difference
was observed between HCC and CRLM patients with re-
gard to duration of hospital stays.
Discussion
RFA has been attracting considerable attention due to
the non-invasive nature of the procedure as well as its
highly predictable therapeutic efficacy [11,12]. However,
for larger tumors, the ablation efficacy of RFA has been
less than satisfactory. Specifically, for tumors exceeding
3 cm, the rate of complete ablation is only in the range
of 11–25% [13,14]. In recent years, the potential applic-
ability of microwave therapy in the treatment of large
liver tumors has become increasingly apparent.
In microwave therapy, a thermal field is created through
the emission of ultra-high-speed electromagnetic micro-
waves from the active tip of the antenna (usually 915 or
2450 MHz). The amount of heat produced in the tissue
depends on water content. Specifically, tissue with higher
water content absorbs more energy, resulting in the pro-
duction of more heat. Like RFA, MWA can be performed
percutaneously, laparoscopically, or during laparotomy.
Percutaneous treatment is less invasive than the other
approaches; it can be performed on an outpatient basis
and can be repeated to deal with recurrent tumors [15].
Surgical ablation, including laparoscopic and laparotomic
approaches, can be applied in locations inaccessible to
percutaneous techniques [15]. In addition, the efficacy of
ablation is superior to that of percutaneous ablation [16].
Early data has suggested that RFA and MWA techniques
have roughly equivalent efficacies with regard to reducing
mortality and the ablation of small HCCs [17-20]. In the
treatment of larger liver tumors, we hypothesizes that
MWA would have an advantage over RFA due to a lower
dependence on tissue properties. In addition, MWA is
capable of consistently generating higher intra-tumoral
temperatures, which accelerate the process of ablation and
make it possible to deal with tumors of greater volume
[21]. This results in the need for fewer applications per
treatment session [22]. The size of the ablation largely
depends on microwave frequency and the permittivity of
tissue to microwave energy. Two frequencies are used for
ablation treatment: 915 mHz and 2450 mHz. The lower
frequency has a longer wavelength (approx. 4.3 cm in
tissue), which results in a higher direct heating efficiency
over a radius of 2.8 cm. In comparison the longer wave-
length of 2450 mHz (approx. 2.8 cm) has a direct heating
efficiency over a 1.1 cm radius. However, Early MWA
systems were unable to respond to feedback at the tissue
level (received through the antennae) during the delivery
of treatment, which can result in thermal cytotoxic changes
at the cellular level that are capable of altering the dielec-
tric properties of the tissue. The amount of energy admin-
istered depends on the temperature of the tissue as well as
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of coagulated tissue (resulting from an increase in tissue
temperature) can decrease the efficacy of ablation treat-
ment [10].
Recently, the microwave device and antenna have re-
cently undergone considerable improvements [23,24].
The MWA system by Medwaves AveCure (San Diego,
CA, USA) has intelligent permittivity feedback control
and probes with unique integrated temperature sen-
sors. These features permit the real-time monitoring of
ablation conditions as well as the modulation of MW
power and frequency (902 MHz – 928 MHz). The heat-
ing of biologically active tissues alters the properties of
permittivity. The feedback control system helps to
improve the adaptability of tissue to microwave radi-
ation. Thus, energy deposition can be maximized and
reverse power can be minimized. Maximizing the
amount of delivered forward power helps to increase
active heating. This in turn induces cellular death more
uniformly throughout the target area. The ability to
control the application of microwave energy makes it
easier to estimate and control the size of the ablation
zone (created by active heat). Moreover, microwave
ablation produces intratumoral temperatures that are
consistently higher than those achieved using other
existing thermo-ablation technologies. Microwave abla-
tion is also effective on tumors of larger volume, and
the process can be completed more quickly, even when
using a single un-cooled antenna. RFA or MWA sys-
tems generally require multiple applicators to create a
large ablation zone. Unfortunately, the insertion of
multiple applicators inevitably increases the technical
difficulty and associated costs of the process, while also
increasing the possibility of complications.
In a recent study evaluating MWA with tumor permit-
tivity feedback in lung tissue, Wolf et al. [10] reported
ablations adjacent to 4 mm vessels with no evidence of
heat sink or collateral vascular damage. Our results,
which demonstrated that MWA can lead to improved
outcomes compared with conventional forms of thermal
ablation, support the findings of Wolf et al.
This is the first study to report on the therapeutic effects
of an MWA system with tumor permittivity feedback
control for the treatment of large liver tumors. In
addition, this study includes a broader cohort than those
considered by previous studies.
This study obtained excellent results using MWA with
tumor permittivity feedback for the treatment of large liver
tumors (>4 cm) using a single antennae (complete tumor
necrosis in 19 of 23 treated tumors). Our study dealt with
tumors 4-7 cm in diameter, 56.5% of which presented the
attachment of hepatic or portal venous trunks. These
tumors were found throughout the entire liver at various
depths. Tumors with these characteristics are generallydifficult to treat using ablation therapy; however, the use
of an uncooled-shaft microwave antenna and repeated
probe insertions resulted in a high rate of complete
ablation (82.6%). The good therapeutic efficacy can be
attributed to the novel MWA system and the type surgi-
cal approach [25] (78.3% of patients in our study under-
went MWA with an open surgical approach). The rate
of complete ablation in this study is higher than that
previously reported using other thermal ablation modalities
such as RFA. Most previous studies attained a complete
ablation rate of only 10–25% for large liver tumors treated
by RFA [13,14]. Our results were also superior to those of
Yin et al. [26] who treated 20 patients with HCC using
2450 MHz MWA system. In that study, the rate of
complete ablation was 65% for large (5.0–7.0 cm) liver can-
cers. However, Xu et al. [27] previously used a multiple
electrode insertion technique, which resulted in a higher
rate of 86.4% for the complete ablation of tumors 4.0 cm
in diameter at 1 month post-ablation.
In the present study, the rates of complete ablation for
HCC and CRLM were 90.0% and 76.9%, respectively.
Just like other series, the effectiveness of ablation in
dealing with CRLM is far lower than when treating HCC
[28]. In addition, the long-term outcome of HCC is gen-
erally superior to that of CRLM [29].
Evaluating the long-term results and survival rates as-
sociated with MWA is beyond the scope of this study;
however, it should be noted that the survival rate in this
relatively short follow up (12 months) was 100%. This
compares favorably with the study of Lu et al. [12], in
which the 1-year survival rate for 36 patients was 96%,
and that of Dong et al. [30], in which the 1-year survival
rate for 185 patients was 92.7%.
MWA appears to have been well-tolerated by our patient
group, with no post-operative deaths and few complications
related to the ablation procedure. Specifically, none of the
patients in this study showed evidence of sepsis, bile duct
damage, uncontrollable bleeding, or significant systemic
upset. This is in stark contrast with RFA studies, which
have reported complications in as many as 33% of patients
[31,32]. In addition, Xu et al. [27] reported a complication
rate of 9.3% related to MWA among nine patients.
The study has a number of limitations. Primarily, it was
a short-term study of limited sample size; therefore, reli-
able long term results and survival rates could not be
properly evaluated. Nonetheless, the current research
was only meant to be a preliminary study to investigate
the technical efficacy and safety of this new MW technol-
ogy, according to surgical approach. We did not deal with
long-term disease-free survival.
Conclusions
The current data supports the feasibility of this new
MW technology in the treatment of large liver tumors.
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quencies in the range of 902 and 928 mHz make it pos-
sible to maintain tissue permittivity dynamically during
the ablation process, thus maximizing the deposition of
energy. This approach represents a safe, fast, and effica-
cious means with which to ablate large tumors. The initial
results are encouraging; however, a larger prospective
study with a longer follow-up period should be performed
to investigate delayed complications and long-term onco-
logic outcomes related to MWA with tumor permittivity
feedback.
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